Locations:
SearchAdvertisement
Retrospective study yields clues to understanding risk of secondary myeloid neoplasms
Novel three-drug regimen used to manage life-threatening developments
Momelotinib, a new JAK inhibitor, inches closer to market approval
Claims data reveal disorder is often overlooked and undertreated
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Management options expand in both inpatient and outpatient settings
Sudden-onset abdominal pain prompts urgent visit
Study reveals characteristics that may spark the development of myelodysplastic syndrome and acute myeloid leukemia
Novel regimen may help overcome the shortcomings of traditional chemotherapy in geriatric population
Follow-up study confirms safety and tolerability of new treatment protocol
Experts highlight the newest, most compelling hematology abstracts
Advertisement
Advertisement